Imara Inc. (Nasdaq: IMRA) is a biotech, clinical-stage firm dedicated to making and selling therapy to treat patients with rare genetic disorders of hemoglobin (Hb).
Imara Inc. (Nasdaq: IMRA), shares dropped -32.57% to $16.00 in the early morning session after the company announced findings from its phase 2a IMR-687 clinical trial in adult sickle cell disease patients (SCD).
The Phase 2a clinical trial consisted of 93 treatments in four sub-studies. It was planned to assess efficacy, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of increased IMR-687 doses once daily for 16 to 24 weeks, whether as a monotherapy or in conjunction with hydroxyurea (HU).
Overall, phase 2a clinical results show that IMR-687 has been well-tolerated following HU at all dosage ranges as a monotherapy. No clinically significant changes in vital signs or electrocardiogram data were observed, including no hypotension or neutropenia in either the monotherapy arms or the combination arms. Prior interim results were published on Populations A and B patients, with A1 and B1 populations being reported for the first time.
